The SHUNT-V Study for Varices

Summary

The purpose of this study is to validate the Disease Severity Index (DSI) from the HepQuant SHUNT Liver Diagnostic Kit (Test) for likelihood of large esophageal varices.

Timeline

Start

2019-01-23

Primary completion

2021-05-07

Completion

2022-10-22

Outcome

Met primary endpoint

paper DSI 18.3 had sensitivity 96.3%-100% for LEV and 97.3%-100% for all significant PH lesions. PMID 39523681 ↗

Publications

• Rahimi RS, Mena E, Lucas KJ, McRae MP, Kittelson J, Imperial JC, Smith AD, Everson GT; SHUNT-V Subjects, Investigators, and Coordinators. HMG-CoA Reductase Inhibitors (Statins) May Preserve Hepatic Function and Reduce Portal-Systemic Shunting in Compensated Advanced Chronic Liver Disease: Results From the SHUNT-V Study. Clin Transl Gastroenterol. 2026 Mar 1;17(3):e00980. doi: 10.14309/ctg.0000000000000980.
• Shiffman M, Reddy KR, Leise MD, Qureshi K, Smith AD, Helmke S, Kittelson J, McRae MP, Imperial JC, Everson GT; SHUNT-V Investigators. Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study. Aliment Pharmacol Ther. 2025 Jan;61(1):75-87. doi: 10.1111/apt.18386. Epub 2024 Nov 10.

Drugs

Indications